Moberg Pharma AB (publ) (STO:MOB)
10.78
-0.12 (-1.10%)
May 6, 2026, 5:29 PM CET
Moberg Pharma AB Revenue
In the year 2025, Moberg Pharma AB had annual revenue of 13.54M SEK with 37.99% growth. Moberg Pharma AB had revenue of 2.07M in the quarter ending December 31, 2025, with 101.36% growth.
Revenue
13.54M
Revenue Growth
+37.99%
P/S Ratio
37.84
Revenue / Employee
2.71M
Employees
6
Market Cap
512.31M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 13.54M | 3.73M | 37.99% |
| Dec 31, 2024 | 9.81M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 207.00K | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EQL Pharma AB | 425.75M |
| Cinclus Pharma Holding AB | 57.47M |
| Nanexa AB | 54.32M |
| Enzymatica AB | 53.06M |
| Cereno Scientific AB | 44.27M |
| Newbury Pharmaceuticals AB | 32.78M |
| Orexo AB | 17.80M |
| Klaria Pharma Holding AB (publ.) | 8.99M |
Moberg Pharma AB News
- 2 months ago - Moberg Pharma AB Transcript: Stora Aktiedagarna 2026 - Transcripts
- 6 months ago - Moberg Pharma and Karo Healthcare enter into an exclusive license agreement for MOB-015/Terclara in Europe, expanding access and growth potential - PRNewsWire
- 1 year ago - Moberg Pharma AB Earnings Call Transcript: Q4 2024 - Transcripts
- 1 year ago - Moberg Pharma AB Transcript: Study Update - Transcripts
- 1 year ago - Moberg Pharma reports topline data in the North American phase 3 study and will regain rights to MOB-015 in EU - PRNewsWire
- 1 year ago - Moberg Pharma AB Earnings Call Transcript: Q3 2024 - Transcripts
- 1 year ago - Moberg Pharma AB Transcript: Study Update - Transcripts
- 1 year ago - Moberg Pharma lowers expectations on primary endpoint in ongoing phase 3 trial following data in a subset of patients - PRNewsWire